Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
Latest Information Update: 04 Jun 2025
At a glance
- Drugs Durvalumab (Primary) ; Olaparib (Primary)
- Indications Endometrial cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 04 Jun 2025 New trial record